Ibere Pharmaceuticals
IBER
IBER was delisted on the 1st of March, 2023.
47 hedge funds and large institutions have $126M invested in Ibere Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 7 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
6% more capital invested
Capital invested by funds: $119M → $126M (+$6.7M)
2% less funds holding
Funds holding: 48 → 47 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
+$3.25M |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$2.5M |
| 3 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$2.44M |
| 4 |
GCL
Glazer Capital LLC
New York
|
+$2.44M |
| 5 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$490K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$2.44M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.26M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.25M |
| 4 |
PI
PEAK6 Investments
Chicago,
Illinois
|
-$496K |
| 5 |
Barclays
London,
United Kingdom
|
-$486K |
IBER Hedge Fund Activity: Q4 2022 in Review
47 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q4 2022, worth a combined $126M — up 5.6% from $119M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IBER and 6 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 7 added.
The largest buyer was HSBC Holdings, opening a new position worth an estimated $3.25M. The largest seller was Cowen and Company, exiting entirely with an estimated $2.44M sold.
- 47 institutional investors held Ibere Pharmaceuticals (IBER) as of Q4 2022, down from 48 in Q3 2022.
- Funds reported $126M of Ibere Pharmaceuticals stock for Q4 2022, up 5.6% quarter-over-quarter.
- 6 funds opened new Ibere Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of -1 holder.
- The largest Ibere Pharmaceuticals buyer in Q4 2022 was HSBC Holdings, an estimated $3.25M added.
- The largest Ibere Pharmaceuticals seller in Q4 2022 was Cowen and Company, an estimated $2.44M sold.
Based on aggregated 13F filings for Q4 2022.